Cardiocast

What comes first with SGLT2 inhibitors – diabetes or heart failure?


 

This week in MDedge Cardiocast: Most tPA-eligible stroke patients now get treated within an hour, atrial fib patients with prior hemorrhagic stroke who get their LAA closed can be safely treated, SGLT2 inhibitors are quickly morphing from diabetes to heart failure drugs, and the MESA cardiovascular disease risk calculator can be an improvement on the ACC/AHA version.

Amazon AlexaApple Podcasts

Google Podcasts

TuneIn

Recommended Reading

Intensified approach reduces long-term heart failure risk in T2DM
Type 2 Diabetes ICYMI
CV outcomes better with SGLT2 inhibitor than DPP4 inhibitor in T2DM study
Type 2 Diabetes ICYMI
Empagliflozin’s heart failure benefits linked to volume drop
Type 2 Diabetes ICYMI
Learn ‘four Ds’ approach to heart failure in diabetes
Type 2 Diabetes ICYMI
Major message: Most heart failure is preventable
Type 2 Diabetes ICYMI
Lower glucose target linked to improved mortality in critically ill
Type 2 Diabetes ICYMI
FDA grants praliciguat Fast Track Designation for HFpEF
Type 2 Diabetes ICYMI
New diabetes drugs solidify their cardiovascular and renal benefits
Type 2 Diabetes ICYMI
SGLT-2 inhibitors promising for heart failure prevention, not treatment
Type 2 Diabetes ICYMI
SGLT2 inhibitors morph into HF drugs
Type 2 Diabetes ICYMI